Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Emodepside in Adults Infected With Trichuris Trichiura and Hookworm

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 8.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female adults aged between 18 and 45 years~* Written and signed informed consent~* Examined by a study physician before treatment~* Provided two stool samples at baseline~* Trichuris trichiura and hookworm EPG ≥ 48 and at least two Kato-Katz thick smears slides with more than one Trichuris trichiura and hookworm eggs~Exclusion Criteria:~* Pregnant or lactating and/or planning to become pregnant within three months after drug treatment~* Type 1 and/or 2 diabetes~* Psychiatric disorders~* History of ophthalmological conditions~* Presence or history of major systemic or chronic illnesses, as assessed by a medical doctor, during initial clinical assessment~* Suffers from severe anaemia (Hb \< 80 g/l)~* Received anthelminthic treatment within past four weeks~* Attending other clinical trials during the study~* Received strong CYP3A4 inducers or inhibitors as well as concomitant treatments that are relevant substrate for CYP3A4 such as clarithromycin, erythromycin and rifampicin~* Received strong P-gp inhibitors as well as concomitant treatments that are relevant substrates for P-gp such as clotrimazole and ritonavir

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Emodepside 5 mg (Type: EXPERIMENTAL): None
- Emodepside 10 mg (Type: EXPERIMENTAL): None
- Emodepside 15 mg (Type: EXPERIMENTAL): None
- Emodepside 20 mg (Type: EXPERIMENTAL): None
- Emodepside 25 mg (Type: EXPERIMENTAL): None
- Emodepside 30 mg (Type: EXPERIMENTAL): None
- Albendazole (Type: ACTIVE_COMPARATOR): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).